APA (7th ed.) Citation

Michallet, M., Dreger, P., Sobh, M., Koster, L., Hoek, J., Boumendil, A., . . . Schetelig, J. (2020). Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia. Bone marrow transplantation, 55(5), . https://doi.org/10.1038/s41409-019-0742-7

Chicago Style (17th ed.) Citation

Michallet, Mauricette, et al. "Ibrutinib as a Salvage Therapy After Allogeneic HCT for Chronic Lymphocytic Leukemia." Bone Marrow Transplantation 55, no. 5 (2020). https://doi.org/10.1038/s41409-019-0742-7.

MLA (9th ed.) Citation

Michallet, Mauricette, et al. "Ibrutinib as a Salvage Therapy After Allogeneic HCT for Chronic Lymphocytic Leukemia." Bone Marrow Transplantation, vol. 55, no. 5, 2020, https://doi.org/10.1038/s41409-019-0742-7.